Suscribirse

The European Psychiatric Association (EPA) guidance on suicide treatment and prevention - 06/02/12

Doi : 10.1016/j.eurpsy.2011.06.003 
D. Wasserman a, , Z. Rihmer b, D. Rujescu c, M. Sarchiapone d, M. Sokolowski a, D. Titelman a, G. Zalsman e, f, Z. Zemishlany e, V. Carli a
a The National Centre for Suicide Research and Prevention of Mental Ill-Health (NASP), Karolinska Institutet, S-171 77, Stockholm, Sweden 
b Department of Clinical and Theoretical Mental Health and Department of Psychiatry and Psychotherapy, Semmelweis University, Faculty of Medicine, Budapest, Hungary 
c Ludwig Maximilians University, Munich, Germany 
d Department of Health Sciences, University of Molise, Campobasso, Italy 
e Geha Mental Health Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 
f Division of Molecular Imaging and Neuropathology, Psychiatry Department, Columbia University, New York, USA 

Corresponding author. Tel.: +46 8 52 48 49 37; fax: +46 8 52 48 77 93.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 13
Iconografías 1
Vídeos 0
Otros 0

Abstract

Suicide is a major public health problem in the WHO European Region accounting for over 150,000 deaths per year.

Suicidal crisis

Acute intervention should start immediately in order to keep the patient alive.

Diagnosis

An underlying psychiatric disorder is present in up to 90% of people who completed suicide. Comorbidity with depression, anxiety, substance abuse and personality disorders is high. In order to achieve successful prevention of suicidality, adequate diagnostic procedures and appropriate treatment for the underlying disorder are essential.

Treatment

Existing evidence supports the efficacy of pharmacological treatment and cognitive behavioural therapy (CBT) in preventing suicidal behaviour. Some other psychological treatments are promising, but the supporting evidence is currently insufficient. Studies show that antidepressant treatment decreases the risk for suicidality among depressed patients. However, the risk of suicidal behaviour in depressed patients treated with antidepressants exists during the first 10–14 days of treatment, which requires careful monitoring. Short-term supplementary medication with anxiolytics and hypnotics in the case of anxiety and insomnia is recommended. Treatment with antidepressants of children and adolescents should only be given under supervision of a specialist. Long-term treatment with lithium has been shown to be effective in preventing both suicide and attempted suicide in patients with unipolar and bipolar depression. Treatment with clozapine is effective in reducing suicidal behaviour in patients with schizophrenia. Other atypical antipsychotics are promising but more evidence is required.

Treatment team

Multidisciplinary treatment teams including psychiatrist and other professionals such as psychologist, social worker, and occupational therapist are always preferable, as integration of pharmacological, psychological and social rehabilitation is recommended especially for patients with chronic suicidality.

Family

The suicidal person independently of age should always be motivated to involve family in the treatment.

Social support

Psychosocial treatment and support is recommended, as the majority of suicidal patients have problems with relationships, work, school and lack functioning social networks.

Safety

A secure home, public and hospital environment, without access to suicidal means is a necessary strategy in suicide prevention. Each treatment option, prescription of medication and discharge of the patient from hospital should be carefully evaluated against the involved risks.

Training of personnel

Training of general practitioners (GPs) is effective in the prevention of suicide. It improves treatment of depression and anxiety, quality of the provided care and attitudes towards suicide. Continuous training including discussions about ethical and legal issues is necessary for psychiatrists and other mental health professionals.

El texto completo de este artículo está disponible en PDF.

Keywords : Suicide, Depression, Psychiatric diagnosis, Prevention, Identification, Treatment


Esquema


© 2011  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 27 - N° 2

P. 129-141 - février 2012 Regresar al número
Artículo precedente Artículo precedente
  • Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression
  • H.-J. Möller, I. Bitter, J. Bobes, K. Fountoulakis, C. Höschl, S. Kasper
| Artículo siguiente Artículo siguiente
  • European Psychiatric Association guidance on the conflicts of interest
  • C. Höschl, L. Fialová

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.